An interventional study of Emily.AI and Manual oxygen titration in Chronic Respiratory Failure, Acute Respiratory Failure and Hypoxemic Respiratory Failure, sponsored by Aether Tech S.L.. Suspended at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Aether Tech S.L. · Not applicable, Interventional, and Treatment
Recruitment temporarily paused pending competent authority (AEMPS) approval of a protocol amendment. Recruitment will resume after approval. Not stopped for safety reasons.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Respiratory Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Respiratory Insufficiency · Spain.
Among the 69 studies in Respiratory Insufficiency with a site in Spain, this one is the 23rd largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2025, is one of 26 with no phase, and was the 57th registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →11 of the 69 studies in Respiratory Insufficiency with a site in Spain are open now. Recruiting first, the newest first:
Hospital del Mar Research Institute (IMIM) · Sites in Spain
Ages 18+
Medipol University · Sites in Spain, Chile, Egypt and 3 more countries
Ages 18–89
Centro de Emergencias Sanitarias 061 Andalucía · Sites in Spain
BioAegis Therapeutics Inc. · Sites in Spain, United States, Belgium and 10 more countries
Ages 18+
University Health Network, Toronto · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 116 across the 38 interventional studies, 298 across the 31 observational. Of the 42 that completed or were terminated, 6 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 69 have an industry lead sponsor. The 10 most frequent:
Aether Tech S.L. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Aether Tech S.L. has 1 study filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
7 of the studies in Respiratory Insufficiency with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07679646Air Liquide Healthcare SpainEffectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO) | 2026-12 |
| NCT07098611Medipol UniversityA New Tool for Extubation Readiness in Mechanically Ventilated Patients: Readiness for EXtubation Score | 2026-12-30 |
| NCT07178483Hospital Universitari de BellvitgeEvaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure | 2027-03-01 |
| NCT05440851University Health Network, TorontoPlatform of Randomized Adaptive Clinical Trials in Critical Illness | 2027-03-31 |
| NCT07708506Jesus VillarIs Hypoxemia Driving Outcome in Acute Hypoxemic Respiratory Failure? (HOMELAND Study) | 2027-07-29 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Respiratory Insufficiency with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient.
Adults with acute respiratory failure admitted to the Respiratory Intermediate Care Unit (RICU) of Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain) receive oxygen titrated automatically by EMILY.AI and, in the same monitoring session, oxygen titrated manually by the nursing team while the device records saturation and flow.
The study measures how much of the time patients stay within their target saturation range under each method, how fast the device corrects deviations, the alerts it generates, nursing workload, oxygen use and patient comfort. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.
Background Oxygen therapy is usually titrated manually. Both hypoxaemia and hyperoxaemia are associated with harm, so keeping patients within a target SpO2 range matters. EMILY.AI combines a medical-grade oxygen valve with rule-based algorithm that sets the oxygen flow from SpO2, heart rate and respiratory rate, with continuous logging of physiological signals, delivered flow and algorithm-recommended flow.
Setting and supervision All sessions take place in the RICU of Hospital Universitario Fundación Jiménez Díaz under continuous supervision by a study physician, with conventional oxygen therapy available as back-up. Patients are classified at inclusion as hypoxaemic (PaCO2 ≤45 mmHg; target SpO2 94-98%) or hypercapnic (PaCO2 >45 mmHg; target SpO2 92-94%). The same patient may take part in more than one session on different days if their oxygen requirement has changed.
Study phases
The substudy has been conducted in successive phases under amendments approved by the Ethics Committee and the Spanish Agency of Medicines and Medical Devices (AEMPS):
Participants are not told which period is automatic and which is manual. The investigators and nursing staff are not masked, for safety reasons.
The protocol FJD-EMILY-23-02 also includes substudies in a conventional hospital ward and during exercise (6-minute walk test), registered separately.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled January-April 2026 (CIP v4.0-v5.0). Same session: \~5 h closed-loop titration by EMILY.AI, then \~5 h manual titration by nursing staff with the device recording only.
Device: Emily.AI · Other: Manual oxygen titration
Participants enrolled June-July 2026 (CIP v6.0). Same paired session, with refined algorithm parameters.
Device: Emily.AI · Other: Manual oxygen titration
Approximately 10 participants (CIP v8.0). Same paired session, with an adjusted parameter.
Device: Emily.AI · Other: Manual oxygen titration
Participants enrolled April-August 2025 and December 2025 (CIP v3.0-v5.0). EMILY.AI titrates oxygen in closed-loop mode under continuous physician supervision; no paired manual period.
Device: Emily.AI
Investigational smart oxygen valve with a rule-based algorithm that adjusts oxygen flow to keep SpO2 within a target range. Other names: EMILY.AI Smart Valve
Standard care: oxygen flow set and adjusted by the unit's nursing team according to usual practice. The EMILY.AI device stays connected and records signals and flow but does not control delivery.
EFFICACY - EVALUATION OF THE RATE THE DEVICE MAINTAINS BLOOD OXYGEN SATURATION LEVELS
Percentage of monitored time with SpO2, measured by pulse oximetry, within the predefined target range (hypoxaemic patients 94-98%; hypercapnic patients 92-94%), without delivering less or more oxygen than required. Compared between the closed-loop period (EMILY.AI) and the manual titration period in the same participant.
Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
ACCURACY - MEASUREMENT OF THE SYSTEM'S ACTION SPEED CORRECTING THE OXYGEN SATURATION LEVELS
Time in seconds from 1) detection of SpO2 outside the target range to the start of correction and 2) the return of SpO2 to the target range.
Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
ALERT SYSTEM - MEASUREMENT OF THE NUMBER OF SYSTEM ALERTS
Number of alerts generated by EMILY.AI for changes in the oxygen saturation of monitored patients.
Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
ALERT SYSTEM - EVALUATION OF THE AUTHENTICITY OF THE SYSTEM ALERTS BY COMPARING THE OXYGEN SATURATION LEVELS WITH A CONVENTIONAL SYSTEM
Proportion of alerts confirmed by the conventional monitor and, in case of discrepancy, by arterial blood gas analysis.
Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
EFFICIENCY - MEASUREMENT OF THE NUMBER OF TIMES THE MEDICAL AND NURSING TEAM MUST ADJUST THE OXYGENATION
Number of nursing or medical interventions to adjust oxygen flow or address oxygenation-related symptoms, compared between the closed-loop and manual periods.
Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
VERSATILITY - COMPARISON OF BLOOD OXYGEN SATURATION LEVELS MAINTENANCE BETWEEN DIFFERENT PROFILES AND SITUATIONS
Percentage of time within the target range compared between hypoxaemic and hypercapnic participants and across clinical situations (bed rest, sitting, eating, physiotherapy).
Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
SAFETY - TIME WITH OXYGEN SATURATION BELOW AND ABOVE THE TARGET RANGE
Percentage of monitored time with SpO2 below and above the target range, as indicators of insufficient or excessive oxygen delivery, compared between periods.
Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
EFFICIENCY - OXYGEN FLOW DELIVERED
Mean delivered oxygen flow (L/min), distinguishing flow delivered while SpO2 was above the target range, compared between periods.
Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
CLINICAL BENEFIT - DYSPNOEA, ACTIVITY TOLERANCE, COMFORT AND SATISFACTION
Participant-reported dyspnoea and tolerance during hygiene, meals and physiotherapy, comfort and satisfaction, measured with Likert-scale questionnaires.
Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
ADAPTABILITY - AGREEMENT BETWEEN PULSE OXIMETER MODELS
Agreement of SpO2 measurements and trends between pulse oximeter models (Nonin, Masimo, Nihon Kohden); acceptable when variability is below 10% and does not affect patient management.
Time frame: During the monitoring session: approximately 5 hours of closed-loop titration followed by approximately 5 hours of manual titration on the same day (closed-loop period only in the initial phase).
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jun 2025 → Mar 2027 and completion Dec 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Recruitment temporarily paused pending competent authority (AEMPS) approval of a protocol amendment. Recruitment will resume after approval. Not stopped for safety reasons.
Recruitment temporarily paused pending competent authority (AEMPS) approval of a protocol amendment. Recruitment will resume after approval. Not stopped for safety reasons.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aether Tech S.L.